Joe Rogan TRT Protocol: The Evidence Base Behind Every Compound

What Joe Rogan Has Publicly Disclosed

Joe Rogan has discussed his hormone and supplement use across episodes of The Joe Rogan Experience spanning more than a decade. He is not guarded about it. On episode #1576 with Mariana van Zeller (2021), he stated plainly: "I take testosterone replacement therapy. I've been doing it since I was about 40." He has also referenced growth hormone use, NAD+ IV infusions, and various peptides in conversations with guests including Dr. Andrew Huberman, Dr. Peter Attia, and Dr. Mark Gordon.

Separating Disclosure from Endorsement

Rogan frames his use as personal experimentation, not medical advice. He has repeatedly told listeners to "talk to a doctor" before trying anything he discusses. This distinction matters for clinical evaluation: his protocol reflects one patient's choices under physician supervision, not a controlled study. Any extrapolation to other populations requires examining the underlying evidence independently.

The Known Components

Based on publicly available podcast statements and social media posts, Rogan's disclosed protocol includes testosterone cypionate injections, growth hormone (likely recombinant HGH), NAD+ IV therapy, vitamin D3, omega-3 fatty acids, and at various times, peptides such as BPC-157 and ipamorelin. He has also mentioned using vitamin B12 injections and athletic greens. This article focuses on the prescription and clinical-grade compounds where peer-reviewed evidence can be assessed [1].

Testosterone Replacement Therapy: The Strongest Evidence in the Protocol

TRT is the most well-studied component of Rogan's regimen. The clinical evidence supporting testosterone replacement in men with documented hypogonadism (total testosterone below 300 ng/dL) is substantial. Rogan has stated his testosterone levels were declining in his late 30s, which aligns with the known trajectory of age-related androgen decline: approximately 1 to 2% per year after age 30, according to data from the Massachusetts Male Aging Study [2].

The TRAVERSE Trial

The Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE) trial, published in The New England Journal of Medicine in 2023, enrolled 5,246 men aged 45 to 80 with hypogonadism and preexisting or high risk of cardiovascular disease [3]. The trial found that testosterone therapy did not increase the incidence of major adverse cardiovascular events compared to placebo (hazard ratio 0.99; 95% CI, 0.81 to 1.21). This was a landmark result. Prior observational studies had raised cardiovascular safety concerns, and the FDA had mandated the trial in 2015.

Endocrine Society Guidelines

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with symptomatic hypogonadism confirmed by two morning total testosterone measurements below 300 ng/dL [4]. The guideline specifies that testosterone cypionate 75 to 100 mg intramuscularly weekly (or 150 to 200 mg every two weeks) is a first-line option. Rogan has described a weekly injection schedule consistent with this approach. The guideline also emphasizes that TRT should not be initiated in men actively seeking fertility, as exogenous testosterone suppresses spermatogenesis.

Body Composition and Functional Outcomes

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies in 790 men aged 65 and older with testosterone levels below 275 ng/dL, showed that one year of testosterone gel improved sexual function, walking distance, and bone mineral density compared to placebo [5]. The sexual function trial demonstrated a mean increase of 0.58 points on the Psychosexual Daily Questionnaire desire domain (P<0.001). These functional benefits are relevant context for Rogan's reported experience of improved energy and recovery.

Growth Hormone: Moderate Evidence, Narrow Indications

Rogan has referenced growth hormone use in multiple episodes, though he provides less detail about dosing than he does with TRT. Recombinant human growth hormone (rhGH) is FDA-approved for adult growth hormone deficiency (AGHD), but its use for anti-aging or performance optimization in adults without documented deficiency sits outside approved indications [6].

What the Clinical Data Shows

A meta-analysis published in Annals of Internal Medicine (Liu et al., 2007) evaluated 31 studies of GH therapy in healthy elderly adults [7]. The pooled results showed a mean increase of 2.0 kg in lean body mass and a decrease of 2.1 kg in fat mass compared to placebo. But adverse effects were frequent: 23.8% of GH-treated subjects experienced soft tissue edema compared to 4.5% on placebo, and 27.5% developed arthralgias versus 15.1% on placebo. Joint pain, carpal tunnel symptoms, and insulin resistance are well-documented dose-dependent side effects.

The IGF-1 Question

Growth hormone exerts many effects through insulin-like growth factor 1 (IGF-1). The concern, raised by epidemiological data, is that persistently elevated IGF-1 levels may be associated with increased cancer risk. A large prospective analysis from the European Prospective Investigation into Cancer and Nutrition (EPIC) found that men in the highest quintile of circulating IGF-1 had a 1.69-fold higher risk of prostate cancer compared to the lowest quintile (95% CI, 1.33 to 2.13) [8]. This association does not prove causation, but it informs the risk calculus for long-term GH use outside of deficiency.

Clinical Takeaway

For a man in his late 50s using GH under medical supervision with regular IGF-1 monitoring, the short-term body composition benefits are real but modest. The long-term safety profile for non-deficient adults remains uncertain. Dr. Peter Attia, a frequent Rogan guest, has stated on his podcast The Drive: "I think growth hormone is one of the most overrated molecules in the longevity space. The risk-benefit ratio just doesn't pencil out for most people."

NAD+ Therapy: Early Science, Limited Human Trial Data

Rogan has spoken enthusiastically about NAD+ IV infusions, describing them as producing noticeable improvements in energy and cognitive clarity. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in hundreds of metabolic reactions, and its intracellular levels decline with age. The question is whether exogenous supplementation meaningfully reverses that decline in humans.

Preclinical Promise

The preclinical evidence is genuinely interesting. Studies in aged mice have shown that supplementation with NAD+ precursors (nicotinamide riboside, or NR, and nicotinamide mononucleotide, or NMN) can restore NAD+ levels, improve mitochondrial function, and extend healthspan markers [9]. A 2013 study by Gomes et al. In Cell demonstrated that raising NAD+ levels in 22-month-old mice reversed age-related mitochondrial dysfunction to levels comparable to 6-month-old mice.

Human Data Gaps

The human evidence is far thinner. A randomized, double-blind, placebo-controlled trial of NR (NIAGEN, 1,000 mg/day for six weeks) in 40 healthy middle-aged and older adults showed a 60% increase in whole-blood NAD+ levels but no significant changes in glucose metabolism, body composition, or blood pressure [10]. A Phase II trial of MIB-626 (a crystalline form of NMN) in 32 overweight adults aged 55 to 80 showed increased blood NAD+ metabolites but similarly modest clinical endpoints [11].

IV vs. Oral Administration

Rogan specifically uses IV NAD+ infusions, which bypass first-pass metabolism and deliver the coenzyme directly into the bloodstream. No published randomized controlled trial has compared IV NAD+ to oral precursors or placebo for any clinical outcome. The theoretical advantage of IV delivery is higher bioavailability. The practical disadvantage is cost ($750 to $1,500 per infusion at most clinics), discomfort (infusions can cause intense flushing and nausea), and the absence of efficacy data supporting this route over oral alternatives.

Peptide Therapy: A Mixed Evidence Field

Rogan has mentioned several peptides over the years, with BPC-157 and ipamorelin appearing most frequently. The evidence behind these compounds varies enormously.

BPC-157

Body Protection Compound 157 is a synthetic pentadecapeptide derived from a protein in human gastric juice. The animal literature is extensive: BPC-157 has shown wound-healing, anti-inflammatory, and cytoprotective effects in rodent models of tendon injury, ligament damage, muscle tears, and GI ulceration [12]. A 2018 review in Current Pharmaceutical Design cataloged positive results across dozens of preclinical studies. Zero Phase I, II, or III human trials have been published. The peptide is not FDA-approved for any indication, and it is classified as a research chemical in the United States.

Ipamorelin

Ipamorelin is a growth hormone secretagogue that selectively stimulates pituitary GH release without significantly affecting cortisol or prolactin levels. A Phase II study evaluated ipamorelin for post-operative ileus recovery after abdominal surgery (N=114), but the trial did not meet its primary endpoint [13]. Pharmacokinetic data in healthy volunteers confirms dose-dependent GH release, but no completed trial has established efficacy for the anti-aging or recovery applications Rogan has discussed.

Regulatory Context

The FDA issued warning letters to several compounding pharmacies in 2023 regarding the sale of BPC-157 and other peptides, citing a lack of evidence that these compounds meet the standards required for pharmacy compounding [14]. This regulatory position is relevant context for anyone considering these compounds based on Rogan's endorsement.

Vitamin D, Omega-3s, and the Over-the-Counter Layer

Not everything in Rogan's stack requires a prescription. He has consistently mentioned high-dose vitamin D3 (reported as 5,000 IU daily) and omega-3 fatty acids.

Vitamin D3

The relationship between vitamin D status and testosterone levels has been examined in observational studies. A cross-sectional analysis of 2,299 men from the European Male Ageing Study found that men with 25-hydroxyvitamin D levels above 30 ng/mL had significantly higher total and free testosterone than those below 20 ng/mL [15]. A small RCT (N=54) of vitamin D supplementation (3,332 IU/day for one year) in overweight men showed a modest but significant increase in total testosterone compared to placebo (from 10.7 to 13.4 nmol/L; P<0.05) [16]. These effects are small. They do not substitute for TRT in a hypogonadal man, but they may contribute to optimizing hormonal milieu.

Omega-3 Fatty Acids

The REDUCE-IT trial (N=8,179) demonstrated that icosapent ethyl (a purified EPA formulation) at 4 g/day reduced major adverse cardiovascular events by 25% compared to placebo in statin-treated patients with elevated triglycerides [17]. Rogan's use of fish oil is less specific in dose and formulation, but the cardiovascular benefit of high-dose EPA is now well-established in at-risk populations.

How to Evaluate a Celebrity Protocol

Celebrity health disclosures like Rogan's reach millions of listeners. That reach creates a responsibility gap: the audience hears the anecdote but not the lab work, the physician consultations, or the monitoring schedule that supports it.

The Supervision Variable

Rogan has stated that he works with physicians and gets regular bloodwork. This is the single most important variable separating his protocol from reckless self-experimentation. The American Urological Association recommends hematocrit monitoring within 3 to 6 months of TRT initiation, then annually, with dose adjustment or therapeutic phlebotomy if hematocrit exceeds 54% [18]. TRT without this monitoring carries a real risk of polycythemia and thromboembolic events.

Context Specificity

Rogan is a wealthy, well-connected man with access to concierge medicine, personalized dosing, and frequent monitoring. His outcomes on any given compound may not generalize to someone ordering the same compound from an unregulated online source without physician oversight. The Endocrine Society guideline explicitly warns against using testosterone for age-related decline in men with normal testosterone levels, noting that "the balance of benefits and risks has not been established" in this group [4].

The Bottom Line on the Evidence

Rogan's protocol contains one well-supported pillar (TRT for documented hypogonadism), one moderately supported but off-label component (growth hormone), and several compounds with preliminary or absent human evidence (NAD+ infusions, BPC-157, ipamorelin). The over-the-counter elements (vitamin D, omega-3s) have reasonable supporting data for general health but are unlikely to produce the dramatic effects Rogan attributes to his overall regimen. The strongest endorsement any physician can give this protocol is conditional: it requires a confirmed diagnosis, individualized dosing, and regular monitoring by a qualified clinician.

The Endocrine Society guideline states it directly: "Testosterone therapy should be offered to men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function, sense of well-being, and bone mineral density" [4]. That is the evidence-based starting point. Everything else in the stack carries progressively less certainty.